AxoGen (NASDAQ:AXGN) Stock Rating Upgraded by StockNews.com

AxoGen (NASDAQ:AXGN) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday.

Other research analysts have also recently issued reports about the company. JMP Securities lifted their price target on AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a report on Friday, August 9th. Raymond James started coverage on AxoGen in a research report on Monday, July 1st. They set an “outperform” rating and a $13.00 target price for the company. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price objective on shares of AxoGen in a research report on Thursday, June 20th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $13.80.

AxoGen Trading Down 2.8 %

Shares of AxoGen stock opened at $13.80 on Wednesday. AxoGen has a 1 year low of $3.45 and a 1 year high of $15.08. The company has a current ratio of 3.51, a quick ratio of 2.32 and a debt-to-equity ratio of 0.70. The company’s fifty day simple moving average is $11.74 and its 200-day simple moving average is $8.76. The company has a market cap of $603.13 million, a price-to-earnings ratio of -27.60 and a beta of 1.12.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. The firm had revenue of $47.91 million for the quarter, compared to the consensus estimate of $43.27 million. As a group, sell-side analysts expect that AxoGen will post -0.33 EPS for the current year.

Hedge Funds Weigh In On AxoGen

Large investors have recently bought and sold shares of the company. Keeley Teton Advisors LLC raised its stake in shares of AxoGen by 135.3% during the 4th quarter. Keeley Teton Advisors LLC now owns 84,725 shares of the medical equipment provider’s stock worth $579,000 after purchasing an additional 48,725 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in AxoGen by 8.6% in the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after buying an additional 1,651 shares in the last quarter. Roubaix Capital LLC acquired a new stake in AxoGen in the first quarter valued at about $351,000. Lazard Asset Management LLC boosted its stake in AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after buying an additional 2,671 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in AxoGen by 8.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock valued at $240,000 after buying an additional 2,204 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.